PMID- 31447011
OWN - NLM
STAT- MEDLINE
DCOM- 20200311
LR  - 20200311
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 124
IP  - 8
DP  - 2019 Oct 15
TI  - Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic 
      Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score.
PG  - 1286-1292
LID - S0002-9149(19)30823-9 [pii]
LID - 10.1016/j.amjcard.2019.07.023 [doi]
AB  - Sudden cardiac death (SCD) is the most life-threating complication of 
      hypertrophic cardiomyopathy. Guidelines of the European Society of Cardiology 
      (ESC) suggest the implantation of an implantable cardioverter defibrillator in 
      primary prevention according to a 5-year risk SCD score >/=6%. The aim of the study 
      is to evaluate the prognostic role of late gadolinium enhancement (LGE) in 
      patients with a 5-year risk SCD score <6%. In this multicenter study, we 
      performed cardiac magnetic resonance in 354 consecutive hypertrophic 
      cardiomyopathy patients (257 males, range of age 54 +/- 17) with a risk SCD score 
      <6% (302 with <4% and 52 with >/=4 and <6% risk). Hard cardiac events, including 
      SCD, resuscitated cardiac arrest, appropriate implantable cardioverter 
      defibrillator interventions, sustained ventricular tachycardia, occurred in 22 
      patients. LGE was detected in a high proportion (92%) of patients with hard 
      cardiac events (p = 0.002). At receiver-operating characteristic curve analysis, 
      LGE extent >/=10% was the best threshold to predict major arrhythmic events (area 
      under the curve: 0.74). Kaplan-Meier curves showed that patients with LGE >/=10% 
      had a worse prognosis than those with lower extent (p < 0.0001). LGE extent was 
      the best independent predictor of hard cardiac events (hazard ratio 1.05; 95% 
      confidence interval [CI] 1.03 to 107; p < 0.0001). The estimates 5-year risk of 
      hard cardiac event was 2.5% (95% CI 0.8 to 4.2) in patients with LGE extent <10% 
      and 23.4% (95% CI 10.2 to 36.5) for those with LGE extent >/=10%. In conclusion, 
      this study demonstrates as the extent of LGE >/=10% is able to recognize additional 
      patients at increased risk for malignant arrhythmic episodes in a population with 
      low-to-intermediate ESC SCD risk score.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Todiere, Giancarlo
AU  - Todiere G
AD  - Fondazione Toscana G. Monasterio, Pisa, Italy.
FAU - Nugara, Cinzia
AU  - Nugara C
AD  - Universita di Palermo, Palermo, Italy; IRCCS Centro Neurolesi "Bonino Pulejo", 
      Messina, Italy.
FAU - Gentile, Giovanni
AU  - Gentile G
AD  - IRCCS-ISMETT, Palermo, Italy.
FAU - Negri, Francesco
AU  - Negri F
AD  - University of Trieste, Trieste, Italy.
FAU - Bianco, Francesco
AU  - Bianco F
AD  - Universita di Palermo, Palermo, Italy; University of Chieti, Chieti, Italy.
FAU - Falletta, Calogero
AU  - Falletta C
AD  - IRCCS-ISMETT, Palermo, Italy.
FAU - Novo, Giuseppina
AU  - Novo G
AD  - Universita di Palermo, Palermo, Italy.
FAU - Di Bella, Gianluca
AU  - Di Bella G
AD  - University of Messina, Messina, Italy.
FAU - De Caterina, Raffaele
AU  - De Caterina R
AD  - University of Chieti, Chieti, Italy.
FAU - Zachara, Elisabetta
AU  - Zachara E
AD  - Ospedale S. Camillo Forlanini, Roma, Italy.
FAU - Re, Federica
AU  - Re F
AD  - Ospedale S. Camillo Forlanini, Roma, Italy.
FAU - Clemenza, Francesco
AU  - Clemenza F
AD  - IRCCS-ISMETT, Palermo, Italy.
FAU - Sinagra, Gianfranco
AU  - Sinagra G
AD  - University of Trieste, Trieste, Italy.
FAU - Emdin, Michele
AU  - Emdin M
AD  - Fondazione Toscana G. Monasterio, Pisa, Italy; Life of Science Institute, Scuola 
      Superiore Sant'Anna, Pisa, Italy.
FAU - Aquaro, Giovanni Donato
AU  - Aquaro GD
AD  - Fondazione Toscana G. Monasterio, Pisa, Italy. Electronic address: 
      aquaro@ftgm.it.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20190729
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Contrast Media)
RN  - AU0V1LM3JT (Gadolinium)
SB  - IM
MH  - Cardiomyopathy, Hypertrophic/complications/*diagnosis/physiopathology
MH  - Contrast Media/pharmacology
MH  - Death, Sudden, Cardiac/epidemiology/*etiology
MH  - Female
MH  - Follow-Up Studies
MH  - Gadolinium/*pharmacology
MH  - Heart Ventricles/*diagnostic imaging/physiopathology
MH  - Humans
MH  - Incidence
MH  - Italy/epidemiology
MH  - Magnetic Resonance Imaging, Cine/*methods
MH  - Male
MH  - Middle Aged
MH  - Myocardium/*pathology
MH  - Prognosis
MH  - ROC Curve
MH  - Retrospective Studies
MH  - Risk Assessment/*methods
MH  - Risk Factors
MH  - Survival Rate/trends
MH  - Ventricular Function, Left/physiology
EDAT- 2019/08/27 06:00
MHDA- 2020/03/12 06:00
CRDT- 2019/08/27 06:00
PHST- 2019/04/01 00:00 [received]
PHST- 2019/07/01 00:00 [revised]
PHST- 2019/07/02 00:00 [accepted]
PHST- 2019/08/27 06:00 [pubmed]
PHST- 2020/03/12 06:00 [medline]
PHST- 2019/08/27 06:00 [entrez]
AID - S0002-9149(19)30823-9 [pii]
AID - 10.1016/j.amjcard.2019.07.023 [doi]
PST - ppublish
SO  - Am J Cardiol. 2019 Oct 15;124(8):1286-1292. doi: 10.1016/j.amjcard.2019.07.023. 
      Epub 2019 Jul 29.